P50 sensory gating studies in schizophrenics: a systematic review

National Medical Journal of China

Volumn 90, Issue 29, 2010, Pages 2020-2025

  Su, Liang ^a   Hu, Hua ^a   Chen, Jing ^a   Wang, Ji Jun ^b   Wang, Li Wei ^a   Shi, Shen Xun ^a  

^a FUDAN UNIVERSITY   (China)

^b NONE

Author keywords

Evoked potentials, auditory; Meta analysis; P50 sensory gating; Schizophrenia

Indexed keywords

PROTEIN P50;

HUMAN; MEDICAL LITERATURE; REVIEW; SCHIZOPHRENIA; SENSORY GATING; SYSTEMATIC REVIEW; ELECTROENCEPHALOGRAPHY; EVOKED AUDITORY RESPONSE; META ANALYSIS; PATHOPHYSIOLOGY;

ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; HUMANS; SCHIZOPHRENIA; SENSORY GATING;

EID: 84871464066     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2010.29.002     Document Type: Review

References (34)

1. Freedman R. Schizophrenia. N Engl J Med, 2003, 349: 1738-1749.
2. De Wilde O M, Bour L J, Dingemans P M, et al. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schiz Res, 2007, 97: 137-151.
3. Brockhaus-Dumke A, Schultze-Lutter F, Mueller R, et al. Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients. Biol Psychiatry, 2008, 64: 376-384.
4. Bramon E, Rabe-Hesketh S, Sham P, et al. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schiz Res, 2004, 70: 315-329.
5. Adler L E, Olincy A, Cawthra E M, et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry, 2004, 161: 1822-1828.
6. 2006, 39: 250-251.
7. 2004, 4: 634-637.
8. Lichtenstein M, Mulrow C, Elwood P. Guidelines for reading case-control studies. J Chronic Dis, 1987, 40: 893-903.
9. Griffith J, Hoffer L, Adler L, et al. Effects of sound intensity on a midlatency evoked response to repeated auditory stimuli in schizophrenic and normal subjects. Psychophysiology, 1995, 32: 460-466.
10. Ebrahim S, Clarke M. STROBE: new standards for reporting observational epidemiology, a chance to improve. Int J Epidem, 2007, 36: 946.
11. 2007, 27: 306-311.
12. Cochrane. http://www.cochrane.org/cochrane/hbook.htm.In.
13. Glasziou P, Oxman A, Higgins J. Summary of Findings Tables within Cochrane Reviews: Draft Specification for RevMan 5.0. Cochrane Collaboration Steering Group, 2005.
14. 2001, 1: 168-169.
15. Rosenberg M. The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis. Evolution, 2005, 59: 464-468.
16. 2001, 27: 203-205.
17. 2006, 39: 193-196.
18. 2008, 20: 261-264.
19. 2009, 22: 29-31.
20. 2009, 89: 2616-2620.
21. Hong X, Chan R C, Zhuang X, et al. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia. Schizophr Res, 2009, 108 151-157.
22. 2010.
23. Sterne J, Egger M, Smith G. Systematic reviews in health care: investigating and dealing with publication and other biases in metaanalysis. BMJ, 2001, 323: 101-105.
24. Egger M, Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997, 315: 629-634.
25. De Wilde O M, Bour L J, Dingemans P M, et al. Failure to find P50 suppression deficits in young first-episode patients with schizophrenia and clinically unaffected siblings. Schiz Bull, 2007, 33: 1319-1323.
26. Clementz B, Geyer M, Braff D. Multiple site evaluation of P50 suppression among schizophrenia and normal comparison subjects. Schiz Res, 1998, 30: 71-80.
27. Lu B, Martin K, Edgar J, et al. Effect of Catechol O-Methyltransferase Val158Met Polymorphism on the P50 Gating Endophenotype in Schizophrenia. Biol Psychiatry, 2007, 62: 822-825.
28. Adler L E, Cawthra E M, Donovan K A, et al. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry, 2005, 162: 386-388.
29. Chung C, Remington G. Predictors and markers of clozapine response. Psychopharmacology (Berl), 2005, 179: 317-335.
30. Wang H, Zhang M, Chen X, et al. P50 auditory sensory gating in first onset schizophrenics and normal healthy adults. Front Med China, 2007, 1: 429-432.
31. 2006, 39: 65-68.
32. Light G A, Geyer M A, Clementz B A, et al. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry, 2000, 157: 767-771.
33. Bramon E, Rabe-Hesketh S, Sham P, et al. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res, 2004, 70: 315-329.
34. de Wilde O M, Bour L J, Dingemans P M, et al. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophr Res, 2007, 97: 137-151.